ACE Inhibitors and ARBs in Diabetic Nephropathy

Introduction to Preferred Antihypertensive Classes

The American Diabetes Association recommends ACE inhibitors and angiotensin receptor blockers (ARBs) as the first-line antihypertensive agents for diabetic nephropathy, providing renoprotection beyond blood pressure lowering alone by reducing intraglomerular pressure and proteinuria 1, 2

For Type 1 diabetic patients with any degree of albuminuria and hypertension, ACE inhibitors are the preferred initial therapy, reducing the risk of death, dialysis, and transplantation by 50% and the risk of doubling serum creatinine by 48% in patients with nephropathy and serum creatinine levels indicating impaired kidney function 2, 3, 4
ACE inhibitors delay progression of nephropathy in both hypertensive and normotensive Type 1 diabetic patients 1, 2

Both ACE inhibitors and ARBs delay progression from microalbuminuria to macroalbuminuria in hypertensive Type 2 diabetic patients 2, 3
ARBs are specifically indicated for Type 2 diabetic patients with macroalbuminuria, elevated serum creatinine levels, and hypertension, reducing progression to end-stage renal disease more effectively than other antihypertensive classes 1, 2

Initiate ACE inhibitor or ARB when albuminuria is present, regardless of blood pressure in many cases, and uptitrate to maximally tolerated dose rather than focusing on which specific agent within the class 2, 3
Target blood pressure <130/80 mmHg for all diabetic patients with nephropathy, and if one class is not tolerated, substitute the other class 2, 3
Add additional antihypertensive agents as needed to reach blood pressure targets, but maintain ACE inhibitor or ARB as the foundation 2, 3
Monitor for hyperkalemia, as both ACE inhibitors and ARBs can exacerbate this condition in diabetic patients 1, 2

Dihydropyridine calcium channel blockers as initial monotherapy are not more effective than placebo in slowing nephropathy progression and should only be used as add-on therapy to ACE inhibitors or ARBs 2, 3
Beyond blood pressure control, ACE inhibitors and ARBs reduce single-nephron hyperfiltration by dilating efferent arterioles, thereby decreasing intraglomerular hypertension that drives progressive kidney damage 1, 4

The American Diabetes Association recommends ACE inhibitors for diabetic patients with early-to-moderate chronic kidney disease (eGFR ≥30 mL/min/1.73 m² with albuminuria) because they slow progression to end-stage renal disease 5, 6

ACE inhibitors provide kidney protection in diabetic patients by reducing intraglomerular pressure through dilation of efferent arterioles, which decreases hyperfiltration injury that drives diabetic nephropathy progression 7, 8
They also reduce proteinuria beyond what blood pressure lowering alone achieves, indicating direct renoprotective effects independent of systemic blood pressure control 7, 8

For Type 1 Diabetes, the American College of Cardiology recommends ACE inhibitors for patients with macroalbuminuria (≥300 mg/g creatinine) and eGFR ≥30 mL/min/1.73 m², where they reduce progression to end-stage renal disease by approximately 50% 7, 9
For Type 2 Diabetes, the American Heart Association recommends ACE inhibitors or ARBs when eGFR <60 mL/min/1.73 m² AND albuminuria ≥300 mg/g creatinine 5, 6

Clinical trials demonstrating ACE inhibitor benefit excluded patients with eGFR <30 mL/min/1.73 m², and at this stage, structural kidney damage is often irreversible 7, 8
The American College of Cardiology advises against combining ACE inhibitor with ARB or direct renin inhibitor, as this increases adverse events without additional benefit 5, 6

When using ACE inhibitors in diabetic kidney disease, monitor serum creatinine and potassium within 7-14 days of initiation or dose change, and accept creatinine increases up to 30% from baseline 6, 10
Discontinue ACE inhibitors if potassium >5.5 mEq/L despite dietary restriction and diuretic adjustment, and hold temporarily during acute illnesses causing volume depletion 10